1. Home
  2. BEAM vs ADUS Comparison

BEAM vs ADUS Comparison

Compare BEAM & ADUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • ADUS
  • Stock Information
  • Founded
  • BEAM 2017
  • ADUS 1979
  • Country
  • BEAM United States
  • ADUS United States
  • Employees
  • BEAM N/A
  • ADUS N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • ADUS Medical/Nursing Services
  • Sector
  • BEAM Health Care
  • ADUS Health Care
  • Exchange
  • BEAM Nasdaq
  • ADUS Nasdaq
  • Market Cap
  • BEAM 1.6B
  • ADUS 2.1B
  • IPO Year
  • BEAM 2020
  • ADUS 2009
  • Fundamental
  • Price
  • BEAM $21.16
  • ADUS $110.83
  • Analyst Decision
  • BEAM Strong Buy
  • ADUS Buy
  • Analyst Count
  • BEAM 11
  • ADUS 10
  • Target Price
  • BEAM $48.90
  • ADUS $143.50
  • AVG Volume (30 Days)
  • BEAM 2.2M
  • ADUS 149.0K
  • Earning Date
  • BEAM 08-05-2025
  • ADUS 08-04-2025
  • Dividend Yield
  • BEAM N/A
  • ADUS N/A
  • EPS Growth
  • BEAM N/A
  • ADUS 9.84
  • EPS
  • BEAM N/A
  • ADUS 4.42
  • Revenue
  • BEAM $63,578,000.00
  • ADUS $1,211,561,000.00
  • Revenue This Year
  • BEAM N/A
  • ADUS $23.16
  • Revenue Next Year
  • BEAM $17.18
  • ADUS $5.77
  • P/E Ratio
  • BEAM N/A
  • ADUS $24.91
  • Revenue Growth
  • BEAM N/A
  • ADUS 11.38
  • 52 Week Low
  • BEAM $13.53
  • ADUS $88.96
  • 52 Week High
  • BEAM $35.25
  • ADUS $136.72
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 65.49
  • ADUS 44.79
  • Support Level
  • BEAM $19.02
  • ADUS $109.93
  • Resistance Level
  • BEAM $22.51
  • ADUS $115.01
  • Average True Range (ATR)
  • BEAM 1.15
  • ADUS 2.69
  • MACD
  • BEAM 0.49
  • ADUS -0.47
  • Stochastic Oscillator
  • BEAM 78.91
  • ADUS 7.48

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.

Share on Social Networks: